Pharmaceuticals; authorize the Division of Medicaid to establish a wholesale prescription drug importation program.
SB 2715 would create the Mississippi Wholesale Prescription Drug Importation Program and assign the Mississippi Division of Medicaid to run it. The program is intended to lower prescription drug costs for consumers in Mississippi by allowing certain prescription drugs available outside the United States, especially through Canadian suppliers, to be imported and dispensed in the state under a regulated framework. The division would have to contract with prescription drug wholesalers and Canadian suppliers, create a registration process for health benefit plans, providers, and pharmacies, publish a list of eligible drugs and prices, and establish outreach, a call center or portal, and other administrative procedures.
The bill limits the program to drugs that meet federal requirements, including FDA safety and effectiveness standards, compliance with federal patent law, and the tracking, tracing, verification, and identification rules in federal law. It excludes controlled substances, biological products, infused drugs, intravenously injected drugs, inhaled surgical drugs, and parenteral drugs. The division would also be required to monitor potential anticompetitive conduct, impose a fee or other funding mechanism if needed, audit participating wholesalers, and report annually to the Governor and Legislature on program participation, prescriptions dispensed, and estimated savings.
The bill would add a new state prescription drug importation program administered by the Division of Medicaid and would codify new reporting requirements in Section 73-21-158 of the Mississippi Code. It would require drug manufacturers to file quarterly wholesale acquisition cost reports and additional price-increase disclosures, and it would require pharmacy benefit managers and health insurers to submit annual reports to the Commissioner of Insurance on rebates, fees, spending, premiums, and utilization management. These provisions would increase state oversight of drug pricing and supply-chain practices while creating new compliance and reporting obligations for manufacturers, PBMs, insurers, wholesalers, providers, and pharmacies. The act would take effect July 1, 2025.
The available record shows no committee transcripts and no recorded votes, so there is no documented debate or formal vote history to indicate support or opposition. Based on the bill text, the measure is framed as a cost-saving and transparency initiative, suggesting a consumer-focused policy rationale. The absence of recorded legislative discussion means the overall sentiment cannot be measured from the provided materials beyond the bill’s stated purpose.
The main potential points of contention are likely to be the legality, feasibility, and market effects of importing prescription drugs from Canada and other outside-U.S. sources, even with federal compliance requirements. The bill also places new reporting burdens on manufacturers, PBMs, and insurers, which may be viewed as intrusive or administratively costly by those industries. In addition, the requirement that the Division of Medicaid monitor anticompetitive activity suggests concern that the program could affect existing drug distribution and pricing markets, while supporters would likely emphasize consumer savings and transparency.